CYCC Aug 2024 2.500 call
- Zacks
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cy
- GlobeNewswire
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from
